author-photo

M. Arbushites

GlaxoSmithKline

23

Papers

1260

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study

2012 Molecular Oncology
Show All
- Source
- Cite
- Save
Citations (60)
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

2012 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (38)
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer

2010 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (27)
A 6 gene molecular predictor of lapatinib related benefit: from cell line models to clinical trials.

2009 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Circulating tumor cell and endothelial cell data from a phase II evaluation of lapatinib and bevacizumab in HER2-overexpressing metastatic breast cancer.

2009 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC).

2009 Cancer Research
Show All
- Source
- Cite
- Save
Citations (16)
Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study

2009 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (51)